PDR001
Phase 2CompletedDevelopment Stage
Well-differentiated Non-functional NET of Thoracic Origin
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
Feb 14, 2017 → May 13, 2020
About PDR001
PDR001 is a phase 2 stage product being developed by Novartis for Well-differentiated Non-functional NET of Thoracic Origin. The current trial status is completed. This product is registered under clinical trial identifier NCT02955069. Target conditions include Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin.
Hype Score Breakdown
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04058756 | Phase 1 | Active |
| NCT02955069 | Phase 2 | Completed |
| NCT02678260 | Phase 1 | Completed |
| NCT02404441 | Phase 1/2 | Completed |
Competing Products
2 competing products in Well-differentiated Non-functional NET of Thoracic Origin
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| sunitinib | Pfizer | Approved | 84 |
| INCMGA00012 + Palbociclib | Incyte | Phase 2 | 49 |